MARKET

FWBI

FWBI

First Wave Biopharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3200
-0.0198
-5.83%
After Hours: 0.3200 0 0.00% 17:26 05/25 EDT
OPEN
0.3300
PREV CLOSE
0.3398
HIGH
0.3400
LOW
0.3158
VOLUME
138.10K
TURNOVER
0
52 WEEK HIGH
9.70
52 WEEK LOW
0.2800
MARKET CAP
5.34M
P/E (TTM)
-0.0286
1D
5D
1M
3M
1Y
5Y
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares rose 20.9% to $0.70 in pre-market trading after dropping 12% on Wednesday. Acorda Therapeutics recently posted a Q1 loss of $1.66 per share.
Benzinga · 6d ago
First Wave BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Investment Conference
Fireside Chat scheduled for Tuesday, May 24, 2022, at 3:00 p.m., EDTBOCA RATON, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company speciali...
GlobeNewswire · 05/17 11:00
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 89.7% to $0.1480 in pre-market trading after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Benzinga · 05/12 10:17
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday.
Benzinga · 05/03 10:08
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; First Wave BioPharma Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 100 points on Monday.
Benzinga · 05/02 19:31
Mid-Day Market Update: Dow Drops Over 100 Points; Hilltop Holdings Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping more than 100 points on Monday.
Benzinga · 05/02 16:17
Why First Wave BioPharma Shares Are Tanking Today
First Wave BioPharma Inc (NASDAQ: FWBI) shares are plummeting after the company reported topline data from Phase 2 RESERVOIR trial of FW-COV, oral formulation of niclosamide, for COVID-19-related GI infections.
Benzinga · 05/02 11:54
BRIEF-First Wave Biopharma - On Apr 27, Board Of Co Approved, Effective Immediately, An Increase In Size Of Board From Six Directors To Seven Directors
reuters.com · 04/29 21:56
More
No Data
Learn about the latest financial forecast of FWBI. Analyze the recent business situations of First Wave Biopharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FWBI stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
High20.00
Average20.00
Low20.00
Current 0.3200
EPS
Actual
Estimate
-2.62-1.96-1.31-0.65
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 36
Institutional Holdings: 2.97M
% Owned: 17.81%
Shares Outstanding: 16.70M
TypeInstitutionsShares
Increased
5
89.24K
New
5
102.41K
Decreased
5
22.55K
Sold Out
4
12.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Sapirstein
Chief Financial Officer
Sarah Romano
Lead Director/Independent Director
Edward Borkowski
Director
David Hoffman
Independent Director
Charles Casamento
Independent Director
Terry Coelho
Independent Director
Gregory Oakes
Independent Director
Alastair Riddell
No Data
No Data
About FWBI
First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

Webull offers kinds of First Wave BioPharma Inc stock information, including NASDAQ:FWBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FWBI stock methods without spending real money on the virtual paper trading platform.